Report Overview

The South Korea myasthenia gravis (MG) therapeutics market size stood at around USD xx million in 2020 and is projected to reach xx million by 2028, exhibiting a CAGR of around xx% during the forecast period.

Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission.MG is the most common neuromuscular junction disorder, although estimates of its frequency vary. It occurs when communication between nerve cells and muscles becomes impaired. This impairment prevents vital muscle contractions from occurring, resulting in muscle weakness. Although there is no cure for the disorder, medications may be used to prevent the aggravation of symptoms.



Market Drivers

The prevalence of MG was 10.42 cases per 100,000 people in 2010 and this increased every year to 12.99 cases per 100,000 people in 2014. The average incidence of MG between 2011 and 2014 was 0.69 cases per 100,000 person-years and it has been increasing continuously. This increase in disease burden is the major factor propelling the market growth.

The prevalence and incidence is found to be higher in the older (50 years) age group than in the younger (<50 years) age group. Hence, aging population also affects the market growth positively.